secwatch.observer — SEC 8-K summary
======================================

Issuer:     KalVista Pharmaceuticals, Inc. (KALV)
CIK:        0001348911
Form:       8-K
Filed at:   2024-09-10T23:59:59+00:00
Accession:  0000950170-24-105182
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KalVista appoints Brian Piekos as CFO effective Sept 9; 100K stock option inducement granted
--------------------------------------------------------------------------------

- Brian Piekos joins as CFO; previously CFO of Elicio Therapeutics and Gemini Therapeutics.
- Piekos receives $460K base salary, 40% bonus target, and 100K stock options at $11.87 with 4-year vest.
- Employment agreements for CEO Ben Palleiko and CMO Paul Audhya amended (severance, Section 280G updates).
- KalVista highlights Piekos' experience as it prepares for sebetralstat commercialization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348911/000095017024105182/0000950170-24-105182-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348911/000095017024105182/kalv-20240906.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-105182

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer